6-K - Can-Fite BioPharma Ltd. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Can-Fite BioPharma Ltd. reported its 2025 financial results and clinical updates, including a $9.83 million net loss, $0.41 million in revenues, and $6.69 million in R&D expenses. Clinical highlights include positive Phase 2a pancreatic cancer data, a 9-year cancer-free survival in an HCC patient on Namodenoson, and advancement of Namodenoson into Phase 3 for hepatocellular carcinoma and Phase 2b for MASH.

Key Takeaways

1Net loss for year ended December 31, 2025 was $9.83 million, up from $7.88 million in 2024.

2Revenues for year ended December 31, 2025 were $0.41 million, down 40% from $0.67 million in 2024.

3R&D expenses for year ended December 31, 2025 were $6.69 million, up 16.26% from $5.75 million in 2024.

4Cash and cash equivalents plus short-term deposits totaled $8.54 million as of December 31, 2025, up from $7.88 million as of December 31, 2024.

5A patient with advanced hepatocellular carcinoma treated with Namodenoson achieved over 9 years of cancer-free survival with complete response.

6Namodenoson is in a Phase 3 study for hepatocellular carcinoma and a Phase 2b study for MASH, with Orphan Drug and Fast Track designations from the FDA.

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Results of Operations

Metric	Value	Basis	Prior Period
Revenue	$405.0K	GAAP	$674.0K
Research and Development Expenses	$6.7M	GAAP	$5.8M
General and Administrative Expenses	$3.7M	GAAP	$3.0M
Net Loss	$-9.8M	GAAP	$-7.9M
Basic and Diluted Net Loss Per Share	$-5.97	GAAP	$-10.86

Exhibits (2)

6-K

REPORT OF FOREIGN PRIVATE ISSUER

99.1

PRESS RELEASE DATED MARCH 26, 2026